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ABSTRACT
We report the case of a renal transplant recipient presenting with elevated serum creatinine levels whilst taking oral
creatine ethyl ester (CEE), but not creatine monohydrate (CM). Standard investigations for allograft dysfunction, including
Doppler ultrasound and renal biopsy, were normal. Serum creatinine normalized following cessation of the supplement.
CM is poorly absorbed and does not affect creatinine. In contrast, CEE is converted and absorbed as creatinine, elevating
serum levels. In such cases, creatinine is not a valid surrogate for glomerular filtration rate (GFR). Alternate methods of GFR
measurement should be considered and a rigorous clinical and drug history taken.
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BACKGROUND
Oral creatine supplements are widely taken to enhance muscle
function and athletic performance [1]. To date, there is an ab-
sence of literature reporting serum creatinine (Cr) rise following
ingestion of creatine in a renal allograft patient.
CASE REPORT
We report the case of a 29-year-old Caucasian male presenting
with elevated serum Cr levels on routine renal transplant clinic
bloods whilst taking creatine ethyl ester (CEE) supplementation.
The patient was 18 months post-transplant with stable 10-
month median Cr of 108 mmol/L receiving standard immuno-
suppression: tacrolimus, prednisolone and mycophenolate
mofetil. Other medications included bisoprolol, ferrous sulphate
and ranitidine. Routine clinic bloods revealed a serum Cr of
245 mmol/L with no change in urea (11.7 mmol/L) from baseline
(Figure 1). All other standard bloods were within normal range.
He had also been taking 3.2 g/day of CEE in the preceding month
and prior to this, 5 g/day of creatine monohydrate (CM) for
6 months. He reported no ill effects and denied taking non-
prescribed medications.
Physical examination revealed a muscular physique weigh-
ing 77.6 kg (Body Mass Index 25.9 kg/m2). Precordial, pulmonary
and abdominal examinations were unremarkable and the pa-
tient was intravascularly replete. Blood pressure was 139/
76 mmHg.
Further investigations were performed. Serum polyomavirus
PCR was undetectable. Tacrolimus trough level was 5.8 ng/mL
and donor-specific Human Leukocyte Antigen Class I/II antibod-
ies were negative. Midstream urine was negative for infection
and albumin: Cr ratio was 1.1 mg/mmol. Doppler ultrasound of
the allograft demonstrated patent vessels, normal intrarenal re-
sistive indices and no hydronephrosis. A kidney biopsy showed
no evidence of acute or chronic tubular damage, nor were there
signs of antibody or T cell-mediated rejection or calcineurin in-
hibitor toxicity. Immunostaining for SV40 and C4d was
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negative. Serum Cr reverted to baseline within 3 days of stop-
ping the CEE.
DISCUSSION
Renal allograft dysfunction is a common complication post-
transplantation and can lead to graft loss. Cr, a product of mus-
cle breakdown, is widely used as a marker of renal function as it
is excreted in the glomerulus and to a lesser extent the proximal
tubule. Cr level is dependent on muscle mass but can be in-
creased by drugs such as trimethoprim and cimetidine through
inhibition of tubular secretion or reduced in liver failure.
Creatine is an ingredient found in fish and meat and is read-
ily available as supplements in CM and CEE forms, with CM be-
ing most widely used [1]. CM is well-studied with trials
suggesting safety when taken at doses of 5–20 g/day [2]. As it is
not degraded during digestion, and 99% is taken up by muscle
or excreted into urine, serum Cr is unaffected [1]. Its side effects
include minor gastrointestinal upset and one reported case
of interstitial nephritis where it was taken at a large dose of
20 g/day for 4 weeks [3].
CEE, also known as creatine ester, is a form of CM with an es-
ter attached in order to increase its bioavailability. CEE has a
comparable creatine content to CM [1], and due to reduced acid
stability is rapidly broken down and absorbed as Cr in the gas-
trointestinal tract, resulting in increased serum Cr [4], rendering
serum Cr no longer a viable surrogate for glomerular filtration
rate (GFR).
Our experience with this patient is consistent with the
known pharmacokinetic differences between CM and CEE: there
was no discernible change from baseline in measured serum Cr
during the 6 months of 5 g/day CM, followed by an acute rise in
Cr following the switch to 3.2 g/day CEE. Both supplements were
taken within recommended dose ranges.
We report this case to raise awareness of a commonly
ingested, performance-enhancing supplement, CEE, which may
give rise to an elevated serum Cr resembling that of advanced
renal dysfunction. Where there is clinical uncertainty, an alter-
native assessment of GFR using cystatin C, iothalamate, iohexol
or 51Cr-EDTA can be considered [5]. We also re-emphasize the
importance of taking a detailed drug history.
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FIGURE 1: CM ingestion (shaded area under dashed line) did not alter serum Cr, which rose acutely after patient switched to taking CEE (shaded area under dotted line).
Serum Cr returned to baseline after cessation of the supplement.
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